VERTEX PHARMACEUTICALS INC / MA Debt Securities, Available-for-sale, Amortized Cost
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Debt Securities, Available-for-sale, Amortized Cost of $7.50 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $7.50B.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $7.18B.
- 2018-03-31: Debt Securities, Available-for-sale, Amortized Cost $1.28B.
- 2017-12-31: Debt Securities, Available-for-sale, Amortized Cost $1.03B.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $7.50B 10-Q · filed 2026-08-04 |
| 2025-12-31 | $7.18B 10-Q · filed 2026-08-04 |
| 2018-03-31 | $1.28B 10-Q · filed 2018-04-27 |
| 2017-12-31 | $1.03B 10-Q · filed 2018-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |